Alectinib Provides a New Option for ALK-positive NSCLC Patients After Progression on Crizotinib

Journal of Community and Supportive Oncology- United States

doi 10.12788/jcso.0277

Full Text

Abstract

Available in

Categories

Date

June 1, 2016

Authors

Jane De Lartigue

Publisher

Frontline Medical Communications, Inc.

Related search

P1.01-101 Survival Benefit of Sequential Therapy in ALK Positive Olioprogressive NSCLC Patients After Crizotinib Resistance

Journal of Thoracic Oncology

Respiratory Medicine

English

Cost Analysis of the Management of Brain Metastases in Patients With Advanced ALK+ NSCLC: Alectinib Versus Crizotinib

Lung Cancer Management

English

The Potential Role of HGF-MET Signaling and Autophagy in the War of Alectinib Versus Crizotinib Against ALK-positive NSCLC

Journal of Experimental and Clinical Cancer Research

Cancer Research

English

P2.13-05 Real-World Clinical Benefit of Continuing Crizotinib Beyond Progression Disease (CBPD) in Patients With Advanced ALK-Positive NSCLC.

Journal of Thoracic Oncology

Respiratory Medicine

English

Crizotinib-Associated Toxic Epidermal Necrolysis in an ALK-positive Advanced NSCLC Patient

Molecular and Clinical Oncology

Cancer Research

English

Alectinib in ALK -Positive, Crizotinib-Resistant, Non-Small-Cell Lung Cancer: A Single-Group, Multicentre, Phase 2 Trial

The Lancet Oncology

English

Pcn172 - Cost-Effectiveness Analysis of Alectinib in Untreated Alk-Rearranged NSCLC Italian Patients

Value in Health

Occupational Health

English

ALK (D5F3) CDx: An Immunohistochemistry Assay to Identify ALK-positive NSCLC Patients

Pharmacogenomics and Personalized Medicine

Molecular Medicine

English

Interstitial Lung Disease Onset and Its Risk Factors in Japanese Patients With ALK-positive NSCLC Following Treatment With Crizotinib

Journal of Thoracic Oncology

Respiratory Medicine

English